California-based, OrsoBio, a biopharmaceutical startup at the clinical stage raised $67 million for developing a treatment for metabolic disorder and obesity, co-led by Woodline Partners & Ascenta Capital in a Series B round.
Enavate Sciences, Longitude Capital, Samsara Biocapital, Eli Lilly and Company, and NuevaBio actively backed the round. After the funds are allocated Co-Founder of Ascenta Capital, Evan Rachlin will join the OrsoBio Board.
California-Based OrsoBio Raised $67M Series B
CEO OrsoBio, MD, PhD Mani Subramanian said in an interview that the funds raised will help OrsoBio in the R&D of the mitochondrial protonophore portfolio and expansion.
OrsoBio is a clinical-stage biopharma company that works on the development of obesity treatment and medical health issues such as severe dyslipidemias, type 2 diabetes, and MASH. OrsoBio has 4 programs that address metabolism issues with the same compound that generates energy in the metabolic process. Currently, the compound is in R&D and it includes:
TLC-6740, TLC-1180, TLC-1235, TLC-3595, and TLC-2716.
Also Read: Infosys McCamish Systems Says IT LockBit Stole 6M People’s Data Ft Toulas Bleepingcomputer